Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer

By S. Tian, Weidong Hu, L. Niu, Huan Liu, Haibo Xu, S. Xiao. Journal of Thoracic Oncology, 2020

1,291 citations recorded by the source corpus.

There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019 (COVID-19), from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma were retrospectively found to have had COVID-19 at the time of the operation. These two cases thus provide important first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that apart from the tumors, the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Because both patients did not exhibit symptoms of pneumonia at the time of operation, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia.

Subfields: Infectious Diseases, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ac49274da67fad0499ff8d28ac625d4fcb7e169e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. J. Chan
2. K. To
3. Shuofeng Yuan
4. Kwok-Yung Yuen

Citations in the corpus

• Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients (2020, neutral): “15 In this study, the elderly population also received Lopinavir and Ritonavir Tablets, and the proportion was not significantly different from the young and middle-aged group.”
• Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series (2020, background): “Early changes of DAD were recently reported for COVID-19 (16, 17).”
• SARS-CoV-2 and viral sepsis: observations and hypotheses (2020, background): “In biopsy or autopsy studies, pulmonary pathology for both early 6 and late phase 7 COVID-19 patients showed diffuse alveolar damage with the formation of hyaline membranes, mononuclear cells, and macrophages infiltrating air spaces, and a diffuse thickening of the alveolar wall.”
• COVID-19 pathophysiology: A review (2020, neutral): “Infiltration of a large number of inflammatory cells were observed in the lungs from severe COVID-19 patients [52,53], and these cells presumably consist of a constellation of innate immune cells and adaptive immune cells.”
• Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients (2020, background): “These phenomena suggest severe pulmonary inflammation and cytokine storm also exist in SARS-CoV-2 infection.”
• Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies (2020, background): “reported on the pulmonary pathology of early-phase COVID-19 in two patients undergoing lung lobectomies for adenocarcinoma [13].”
• Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 (2020, result): “The histopathologic changes in most of our cases with diffuse alveolar damage as the main finding resemble those described by Xu and colleagues (7) and Barton and colleagues (8), who reported single cases; Zhang and colleagues (26), who reported on lung biopsy in a patient with SARS–CoV-2 positivity”
• AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app (2020, background): “Recent studies show that in COVID-19 infected people, there are distinct early pulmonary pathological signs even before the onset of the symptoms of COVID-19 such as dry cough, fever and some difficulty in breathing [23].”